Dendreon
Biotechnology company focused on cancer.
Headquarters:
3005 First Ave.
Seattle, WA 98121
Employees: 1,915
CEO: Dr. Mitchell Gold
Stock Symbol: DNDN
Website:
http://www.dendreon.com
Career
Site
Dendreon is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.
The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.
In April 2010, the FDA approved the use of Provenge, a prostate cancer vaccine developed by Dendreon. The cost for using Provenge for treatment is $93,000.
In 2010, the company reported revenues of $48.0 million and net loss of $439.4 million.
The company announced weaker than expected sales of Provenge in September and said it will cut 500 jobs.
Benefits
Three weeks vacation for all employees. Company is shut down from Christmas to New Year's Day.
Dendreon will pay the premium for:
- Life Insurance
- Accidental Death & Dismemberment
- Short-Term & Long-Term Disability
- Employee Assistance Program
Other benefits include:
- 40 hours of sick leave per year
- Matching 401(k) plan
- Employee Stock Purchase Program
- Flexible Spending
- Voluntary Life Insurance
- Public transportation subsidy
- Tuition subsidy program
- Free fitness center on-site in Seattle
- Discounts to local gyms
Updated September 8, 2011
|